B
Bull
Bull · 25%IRON
$65.75
Scenario price
$55.740
-0.847 (-1.52%)At close
Loading chart…
- High
- 58.835
- Open
- 56.210
- VWAP
- 56.69
- Volume
- 430.72K
- Mkt Cap
- 1.10B
- Low
- 55.480
- Amount
- 24.42M
- EV/EBITDA, TTM
- 0.00
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
AI analysis of Disc Medicine Inc (IRON)
SellDisc Medicine Inc is not a good buy right now due to its current price of $62.06, which is significantly below the analyst price targets of $85 to $86, indicating potential upside. However, the stock has a low RSI of 34.665, indicating it is oversold, but the negative catalysts such as consistent losses with a net income of -63,504,000 USD in Q1 2026 and a declining stock price trend (-21.53% YTD) raise concerns.
Valuation Metrics
The current forward P/E ratio for Disc Medicine Inc (IRON) is 0.00, compared to its 5-year average forward P/E of -11.00.
Alphio AI Price Scenarios for IRON
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding IRON
Events Timeline
News
7.010-02PRnewswireRosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
7.009-26PRnewswireRosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
7.009-21PRnewswireRosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
7.009-17PRnewswireRosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
7.009-11PRnewswireRosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
IRON FAQ — answered by Alphio AI
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Disc Medicine Inc is not a good buy right now due to its current price of $62.06, which is significantly below the analyst price targets of $85 to $86, indicating potential upside. However, the stock has a low RSI of 34.665, indicating it is oversold, but the negative catalysts such as consistent losses with a net income of -63,504,000 USD in Q1 2026 and a declining stock price trend (-21.53% YTD) raise concerns.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.